

Corporate Profile

The Company, together with its subsidiaries and a jointly-controlled entity (the "Group"), is one of the leading pharmaceutical entities principally engaged in the research and development, manufacturing and sales of biopharmaceutical, modernized Chinese pharmaceutical and chemical medicines in the People's Republic of China (the "PRC").

The Group's aim: bring healthier lives to people and greater value to its shareholders by developing innovative biopharmaceuticals and modernized Chinese medicines.

The Group's focus is on therapeutics for liver diseases, ophthalmic diseases, illnesses associated with aging, external use to treat skin diseases, cardio-cerebral diseases and osteoarthritis.

The Group's principal products: Moisten eyedrops, Mioclear eyedrops, Diammonium Glycyrrhizinate injections and capsules, Tianqingfuxin injections and capsules, Alproxladiol injections, Spring injections, Sofast injections, Carnet injections, Zegui Longshuang capsules and Hepudiod cream.

The Group, managed by experienced senior management, is supported by some of the country's top researchers and an extensive sales network. It has been awarded 14 Good Manufacturing Practice ("GMP") in respect of its production facilities for large volume injections, small volume injections, powder injections, ointments, tablets, capsules, eye ointments, eye drops, nose drops, ear drops, powders, granules, liniments and PVC-free soft bags for intravenous injection.

Shandong Chia Tai Freda Pharmaceutical Co., Ltd. ("CTF"), Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd. ("JCTT"), Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. ("NJCTT") and Beijing Chia Tai Green Continent Pharmaceutical Co., Ltd. ("CT Green Continent") are the principal subsidiaries of the Group, while Beijing Tide Pharmaceutical Co., Ltd. ("Beijing Tide") is a jointly-controlled entity of the Group.

According to statistics in Chinese Medicine Statistics Annual Report 2003, CTF, JCTT, Chia Tai Qingshunbao Pharmaceutical Co., Ltd. ("CTQ") and Beijing Tide were ranked among the top 100 Chinese medicine entirely independent audited enterprises based on aggregated profit.

The Company moved the listing from the Growth Enterprise Market ("GEM") of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") to the Main Board on 8 December, 2003.

Stock Code: 1177

Website: www.sino-biopharm.com

